B-cell Malignancy
3
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BeOne MedicinesCA - San Carlos
2 programs2
BGB-16673Phase 1/21 trial
BGB-16673Phase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
BeOne MedicinesBGB-16673
BeOne MedicinesBGB-16673
CRISPR TherapeuticsCTX110
Clinical Trials (3)
Total enrollment: 787 patients across 3 trials
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Start: Nov 2024Est. completion: Dec 202980 patients
Phase 1/2Recruiting
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Start: Sep 2021Est. completion: Nov 2029614 patients
Phase 1/2Recruiting
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Start: Jul 2019Est. completion: Oct 202493 patients
Phase 1/2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 787 patients
2 companies competing in this space